Assisted Reproductive Technology Market Size, Share & Forecast 2026-2033

Overview

The global assisted reproductive technology (ART) market size was valued at USD 30.1 billion in 2025 and is projected to reach USD 49.2 billion by 2033, growing at a CAGR of 6.3% during the forecast period 2026-2033. As the largest segment of the broader reproductive medicine market and fertility treatment market, ART covers the full range of medical procedures used to treat infertility, from in vitro fertilization (IVF), commonly known by the lay term test tube baby treatment, and intracytoplasmic sperm injection (ICSI) to artificial insemination, egg and embryo cryopreservation, and donor-assisted conception, along with the instruments, culture media, and consumables that fertility clinics and cryobanks rely on to deliver them.

The rising number of infertility cases globally is a key driver behind the market's growth, and that burden is shared across both sexes rather than concentrated in women alone: male factors contribute to roughly 40% to 50% of all infertility cases, whether alone or in combination with female factors, according to clinical literature on the topic, even though public awareness and research funding have historically skewed toward female reproductive health. A February 2025 study published in EMJ, based on Global Burden of Disease 2021 data, found that infertility rates have steadily increased from 1990 through 2021, with projections indicating further growth through 2036, a trend particularly concerning in low- and middle-income countries where healthcare infrastructure may not adequately support timely diagnosis and treatment.

The World Health Organization reported in April 2023 that approximately 1 in 6 adults globally, about 17.5% of the adult population, experience infertility at some point in their lives, a prevalence the Lancet Regional Health journal has since flagged as reaching 23.2% in the Western Pacific region specifically. As awareness and diagnosis improve, demand for ART services extends well beyond conventional IVF into a broader set of use cases: fertility preservation for patients delaying parenthood or facing chemotherapy; donor egg, sperm, and embryo programs serving LGBTQ+ patients, single parents, and patients of advanced maternal age; and cross-border reproductive care for patients seeking treatment unavailable or unaffordable at home.

In response to this growing and increasingly diverse demand, investment and innovation in the assisted reproductive technology space are accelerating. In March 2025, Astorg, a prominent pan-European private equity firm, announced the formation of Nexpring Health, a global MedTech company focused solely on assisted reproductive technology. This strategic move reflects the expanding role of private equity in shaping the future of fertility care and scaling access to advanced reproductive technologies, illustrating the assisted reproductive technology market's evolution from a niche medical service into a mainstream, technology-driven sector addressing one of the most pressing public health challenges of our time.

Drivers

Rising Prevalence of Infertility and Increasing Awareness of Reproductive Health

The rising global prevalence of infertility, combined with increasing public awareness and improving access to diagnosis, is creating sustained structural demand for assisted reproductive technology services worldwide. A February 2025 study published in EMJ, based on Global Burden of Disease 2021 data, confirmed that infertility rates have steadily increased from 1990 through 2021, with projections indicating further growth through 2036, and highlighted the particular burden in low- and middle-income countries where healthcare infrastructure may not adequately support timely diagnosis and treatment.

Government support is further expanding the assisted reproductive technology market outlook. In February 2025, the U.S. President issued an executive order aimed at reducing the financial and regulatory burdens associated with IVF treatments, mandating the development of policy recommendations within 90 days to safeguard reproductive healthcare access and lower treatment costs. This initiative is expected to significantly broaden the availability of fertility care, especially for underinsured and economically disadvantaged populations.

Male Infertility Is an Underappreciated but Structurally Significant Demand Driver

Female-side conditions receive the bulk of public and clinical attention. But male factors contribute to roughly 40% to 50% of all infertility cases, whether alone or combined with a female factor. A growing body of research now treats the decline in male fertility as settled science rather than a contested hypothesis. A review in PMC noted that multiple corroborating studies have confirmed a sperm count decline and reduced semen quality in men across the Western hemisphere over recent decades, and that idiopathic infertility, cases with no clearly identified cause, represents nearly 44% of male infertility diagnoses. Obesity, smoking, and heavy alcohol use are established contributors to reduced sperm concentration, motility, and morphology. A 2025 Lancet Regional Health analysis specifically flagged male infertility as an under-addressed factor behind the Western Pacific region's elevated infertility rate. Chronic exposure to environmental toxins and endocrine-disrupting chemicals, including heavy metals such as cadmium and lead and everyday industrial compounds such as phthalates and bisphenol A, is increasingly implicated alongside delayed fatherhood as a compounding factor.

These factors are expanding the pool of male patients who require ICSI, sperm retrieval procedures, or donor sperm to conceive. That growing patient pool directly reinforces demand for the sperm analyzer systems and micromanipulation instruments covered in this report's segment analysis, positioning male-factor diagnostics and treatment as a durable, currently under-served growth line rather than a secondary consideration within the broader ART market.

Technological Advancements in AI and Laboratory Automation

Technological advancements are playing a transformative role in driving the growth and effectiveness of assisted reproductive technology. Innovations in artificial intelligence, automation, and data-driven platforms are enhancing every stage of the fertility treatment process, from diagnosis to embryo transfer, improving clinical outcomes while increasing accessibility and reducing human error. In March 2025, Alife Health expanded its partnership with US Fertility to deliver AI-powered IVF laboratory reports, personalized for each patient, to patients across more than 100 clinics and 32 laboratories in the United States, improving embryo grading and clinical workflow transparency. In April 2025, Conceivable Life Sciences achieved a successful birth from an AI-automated IVF procedure using ICSI, remotely operated by engineers and fertility specialists across 23 automated steps from sperm selection to embryo evaluation, an early but significant proof point for more scalable, cost-effective IVF delivery in regions with limited fertility infrastructure.

Restraint

High Treatment Costs and Limited Insurance Coverage for ART Procedures

Despite strong demand drivers, the global ART market faces significant structural constraints from the high cost of fertility treatments and limited insurance or public health coverage in most markets. A single IVF cycle can cost between USD 12,000 and USD 25,000 in the United States, with multiple cycles often required to achieve a successful pregnancy, representing a significant financial barrier for many patients, particularly where ART procedures are not covered by national health insurance systems or employer-sponsored health plans.

Limited insurance coverage is a systemic challenge across most global markets. While some U.S. states mandate fertility treatment coverage and countries including Israel, Denmark, and Belgium offer government-subsidized IVF cycles, the majority of ART patients globally pay out-of-pocket. This financial burden not only limits access for lower-income populations but also creates geographic disparities in ART utilization, concentrating demand in affluent urban centres while leaving significant unmet need in rural areas and lower-income countries, a gap that directly fuels the cross-border reproductive care patterns discussed in this report's trends analysis.

Reimbursement Models Vary Sharply, and That Variation Shapes Where and How Patients Access Care

Four distinct reimbursement models coexist globally, and which one a patient falls under is often the single biggest determinant of access. Public reimbursement, the most generous model, is exemplified by Israel, which funds largely unrestricted IVF cycles for citizens, and by Denmark and Belgium, which offer government-subsidized cycles within defined limits. Employer-sponsored coverage, a purely private-market response to the same affordability problem, has expanded rapidly in the U.S. through benefits administrators such as Progyny that manage fertility benefits on behalf of large employers, alongside direct employer programs at major technology and finance companies. Private insurance coverage outside employer plans remains patchy and jurisdiction-specific, mandated in some U.S. states and largely absent in others. Self-pay remains the default model for the majority of ART patients worldwide, particularly outside North America, Western Europe, and Israel, and it is this self-pay majority that ultimately drives much of the cross-border reproductive care and cost-arbitrage behavior described elsewhere in this report.

Assisted Reproductive Technology Market Trends & Opportunities

The Fertility Preservation Market and Elective Egg Freezing Are Among the Category's Fastest-Growing Segments

Egg freezing, clinically known as oocyte cryopreservation, has moved well beyond its original oncofertility use case, where patients preserve eggs before chemotherapy or radiation, into mainstream elective use by patients delaying parenthood for career, educational, or personal reasons. In the United Kingdom, the HFEA reported that egg-freezing cycles rose from 4,700 in 2022 to 6,900 in 2023, representing 7% of all treatment and storage cycles, with the largest increases among patients in their thirties. U.S. employer-sponsored benefits are reinforcing this shift, with major employers including Apple, Alphabet, Meta, and Microsoft offering egg-freezing coverage worth roughly USD 20,000 to USD 75,000 per employee. California's SB 729, which mandates coverage for three completed oocyte retrievals plus unlimited embryo transfers on large-group health plans, was originally set to take effect in July 2025 but was delayed by the state legislature to January 1, 2026. For fertility clinics and cryobanks, this shift represents a durable new revenue category within the wider fertility services market, layered on top of conventional infertility treatment rather than a substitute for it.

Donor Egg, Sperm, and Embryo Programs Are Expanding Access for LGBTQ+ Patients, Single Parents, and Advanced-Maternal-Age Patients

Donor egg programs and the wider donor-assisted conception category are growing as a distinct segment driven by patient groups whose family-building needs conventional own-gamete IVF cannot address: LGBTQ+ couples and single parents by choice who require donor sperm, donor eggs, or both, and patients of advanced maternal age whose own egg quality makes donor eggs the more clinically appropriate path to pregnancy. Legal change can shift demand quickly: France's 2021 law extending IVF access to single women and lesbian couples was followed by a sharp, well-documented rise in treatment requests from those newly eligible groups, illustrating how much latent demand exists once legal barriers are removed. Spain and the Czech Republic have built the deepest anonymous donor-egg pipelines in Europe, making them primary destinations for patients from more restrictive markets such as the United Kingdom, where donors must be identifiable to offspring at age 18.

Cross-Border Reproductive Care Is a Structurally Significant, Fast-Evolving Demand Channel

Cost differences and legal access, not clinical quality alone, are the primary forces behind cross-border reproductive care: a standard IVF cycle averaging over USD 20,000 in the United States compares with roughly USD 3,000 to USD 8,000 across Turkey, the Czech Republic, Greece, and India, and comparable savings in Mexico and Thailand, drawing patients from higher-cost markets in significant numbers. Regulatory frameworks governing the global surrogacy market shift quickly and can redirect patient flows with little notice: Greece amended its surrogacy law in May 2025 to require both the intended parent and the surrogate to be legal residents, effectively closing the country to new international surrogacy arrangements after a clinic scandal in Crete, even as Greece remains open to international IVF and donor-egg patients more broadly. For fertility networks operating across multiple jurisdictions, staying current with this kind of fast-moving regulatory change is now a core part of managing an international patient pipeline rather than a peripheral compliance concern.

The Cryopreservation Market and Laboratory Automation Are Advancing Together as a Combined Growth Vector

Cryopreservation sits at the intersection of several demand drivers covered elsewhere in this report: fertility preservation, donor programs, and repeated IVF cycles that generate surplus embryos for storage, the basis of embryo banking, all depend on the same underlying vitrification and storage infrastructure. Laboratory automation is scaling alongside this demand, with automated cryogenic storage and tracking systems increasingly adopted to reduce manual handling error in an application where a single misidentified specimen carries acute clinical and legal stakes. Time-lapse incubators, which continuously image developing embryos without removing them from controlled culture conditions, are similarly moving from a premium differentiator toward a standard lab fixture at larger clinic networks, reinforcing demand for the embryo culture media and cryopreservation media covered in this report's segment analysis.

Digital Health and Genetic Testing Are Expanding the ART Technology Stack Beyond the Lab

The ART technology stack is expanding outward from the embryology lab into diagnostics and care delivery patients interact with directly. Preimplantation genetic testing (PGT), which screens embryos for chromosomal abnormalities or specific inherited conditions before transfer, is increasingly bundled with standard IVF cycles rather than offered as a separate add-on, improving selection accuracy alongside the AI-based embryo grading tools described in this report's driver analysis. Home fertility diagnostics, covering at-home hormone testing kits and ovulation tracking, and tele-fertility consultations are lowering the barrier to a patient's first conversation with a specialist, particularly valuable in regions with limited local clinic density. Robotics is extending into the IVF laboratory itself, building on the automated ICSI workflow Conceivable Life Sciences demonstrated in April 2025, described in this report's driver analysis, as a proof point for scaling automated laboratory procedures beyond a single pilot birth.

Regulatory Analysis

ART regulation varies enormously by jurisdiction, and that variation is itself a structural feature of the market rather than a footnote, directly shaping where the cross-border reproductive care patterns described in this report's trends analysis flow. In the United States, ART clinics and tissue banks are regulated by the FDA primarily as human cell and tissue establishments under 21 CFR Part 1271, a framework focused on donor screening and infectious disease testing rather than a comprehensive national ART law, leaving most substantive practice regulation to individual states. The United Kingdom sits at the opposite end of the spectrum: the HFEA licenses every clinic, sets a default embryo and gamete storage limit, and requires that sperm and egg donors be identifiable to any resulting child once that child turns 18.

The European Union's Tissues and Cells Directive establishes baseline safety and quality standards for donor eggs, sperm, and embryos across member states, but leaves core questions, including donor anonymity, embryo storage duration, and who may legally access treatment, to individual national law, which is precisely why donor and access rules differ so sharply between Spain, the Czech Republic, France, and Greece despite all four operating under the same EU tissue-safety baseline. Surrogacy regulation shows the widest divergence of any ART practice: commercial surrogacy is banned outright in most EU member states, permitted with legal safeguards in several U.S. states, and, as this report's trends analysis details, was significantly narrowed in Greece in May 2025 following a clinic scandal, while remaining broadly available in parts of Latin America under court oversight. For multinational fertility networks and cross-border patients alike, tracking this fragmented and periodically shifting regulatory map is a core operating requirement rather than a background compliance exercise.

Segment Analysis

The global assisted reproductive technology industry is segmented based on type, product type, patient type, end user, and region.

Female Patient Type Holds the Largest Segment Share

Female patient type held a market revenue share of more than 62% in 2025. The female segment is witnessing significant growth in the ART market, driven by rising infertility rates among women, greater societal acceptance of delayed parenthood, and increasing awareness of reproductive health conditions such as PCOS and endometriosis. More women are proactively seeking fertility treatments due to career planning, lifestyle choices, and underlying health conditions, positioning women as primary decision-makers and consumers in the ART space. In November 2024, SpOvum introduced SpOvum ARTGPT, an AI-powered assistant designed to improve patient engagement throughout the fertility journey, offering personalized guidance and strengthening communication between women and fertility clinics.

IVF Leads Overall Volume, While Artificial Insemination Remains the Preferred First-Line Treatment for Milder Cases

In vitro fertilization is the dominant ART type by revenue, with IVF with ICSI gaining the largest share within it due to its effectiveness in male factor infertility cases, supported by innovations in intracytoplasmic sperm injection automation and embryo evaluation. Artificial insemination, most commonly performed clinically as intrauterine insemination (IUI), plays a distinct and durable role rather than a diminishing one: it costs a fraction of a full IVF cycle, typically hundreds to low thousands of dollars against IVF's tens of thousands, and clinical guidelines generally position it as the first-line treatment for unexplained infertility, mild male factor infertility, and cases involving donor sperm where the female partner has normal ovarian reserve and open fallopian tubes. Because many patients and insurers require documented IUI failure before authorizing IVF coverage, artificial insemination functions as a structural gateway into the ART pathway rather than a shrinking legacy category, and it continues to see steady utilization particularly among younger patients and donor-sperm recipients for whom the lower cost and lower physical burden make it the rational starting point.

Instruments and Media Product Segments Are Growing on Distinct Technology Cycles

Within product type, instruments such as embryo incubators, time-lapse incubators, sperm analyzer systems, and micromanipulators are seeing sustained capital investment as fertility clinics scale capacity and compete on lab technology, with time-lapse incubation in particular growing as clinics seek to reduce embryo handling and improve selection accuracy through continuous imaging rather than periodic manual inspection. Media, covering embryo culture media, cryopreservation media, and semen and ovum processing media, represents a recurring, per-cycle consumable spend that scales directly with procedure volume rather than capital cycles, making it a more stable, higher-frequency revenue line for suppliers than instruments. Consumables, including cryovials, storage containers, and culture dishes, are growing in step with the cryopreservation and fertility preservation trends described elsewhere in this report, since every frozen egg, sperm sample, or embryo requires dedicated single-use storage and handling consumables that scale directly with rising freeze volumes.

Fertility Clinics Lead End-User Demand, While Cryobanks and Research Institutes Serve Distinct, Growing Roles

Fertility clinics are the largest end-user segment, capturing the majority of ART procedures globally and anchoring the wider fertility clinic market as specialized centres invest in the embryo incubators and sperm analyzer systems described elsewhere in this report. Cryobanks occupy a smaller but structurally important role distinct from clinics: rather than performing IVF cycles themselves, they specialize in long-term storage of eggs, sperm, and embryos, a function whose growth is closely tied to the fertility preservation, donor program, and repeated-cycle dynamics covered in this report's trends analysis, and one that scales somewhat independently of clinic-level procedure volume since a single frozen specimen can remain in paid storage for years before any clinical procedure occurs against it. Research institutes represent a smaller end-user category focused on reproductive biology, embryo development, and stem-cell research rather than direct patient treatment; while they contribute a modest direct revenue share, they function as an early-adoption channel for new culture media, cryopreservation techniques, and genetic screening methods that later migrate into mainstream clinical use, making the segment disproportionately influential relative to its size.

Geographical Penetration

North America Assisted Reproductive Technology Market: Supportive Policy Frameworks Driving Growth

North America held a significant market revenue share of 45% in 2025. The North America ART market, particularly in the United States, is experiencing significant growth due to a combination of medical demand, supportive policy frameworks, and strategic industry advancements. A primary medical driver is the high prevalence of polycystic ovary syndrome (PCOS), which affects an estimated 6% to 13% of U.S. women of reproductive age, equating to around 5 to 6 million women, of whom up to 70% of cases may go undiagnosed. The February 2025 executive order aimed at reducing IVF financial and regulatory burdens, detailed in this report's driver analysis, is expected to further broaden fertility care availability in the region, especially for underinsured populations.

Europe Assisted Reproductive Technology Market: Driven by Supportive Regulations and a Deep Fertility-Tourism Ecosystem

Europe represents the second-largest regional market, supported by advanced healthcare infrastructure, relatively favourable regulatory frameworks, and a network of specialized fertility clinics across the United Kingdom, Spain, Germany, France, and the Czech Republic. Several European countries including Denmark, Belgium, and Israel offer government-subsidized IVF cycles, improving affordability relative to markets relying solely on private pay. Spain and the Czech Republic have emerged as the region's leading cross-border reproductive care destinations, built on deep anonymous donor-egg pipelines and competitive pricing that attract patients from across Europe, while Greece has long been known for permissive access, including for single women and patients up to age 54, though its May 2025 surrogacy law change now requires both intended parent and surrogate to hold Greek residency, narrowing the country's role specifically for international surrogacy arrangements even as it remains open to IVF and donor-egg patients. The UK's Human Fertilisation and Embryology Authority maintains one of the world's most comprehensive ART regulatory frameworks, and the region's leading ART technology developers, including Vitrolife, CooperSurgical, and Esco Micro, continue to support innovation in embryo culture media, cryopreservation, and laboratory instruments.

Asia-Pacific Assisted Reproductive Technology Market: Fastest Regional Growth on Affordability and Rising Domestic Demand

Asia-Pacific is the fastest-growing regional ART market, driven by a combination of rising domestic infertility diagnosis, expanding clinic capacity, and the region's position as a leading low-cost fertility tourism destination. India offers among the world's most affordable IVF, with cycles typically costing a fraction of U.S. prices, drawing both domestic patients and international medical travelers, while its clinics increasingly compete on both cost and clinical quality. China's ART demand is being shaped by its own demographic policy shift toward encouraging higher birth rates, expanding the domestically funded patient pool, while Thailand has built a strong private fertility tourism sector serving patients across Asia, the Middle East, and beyond. The Lancet Regional Health has specifically flagged the Western Pacific region's infertility prevalence at 23.2%, above the global average, underscoring the scale of underlying demand still to be addressed through expanded clinic capacity across the region.

South America Assisted Reproductive Technology Market: Growing on Expanding Private Clinic Networks

Brazil anchors the South American ART market, supported by a growing private fertility clinic network in major urban centres and rising diagnosis rates as awareness of infertility as a treatable medical condition improves. Argentina's smaller but developing fertility sector is contributing secondary regional demand, and both markets benefit from comparatively lower treatment costs than North America or Western Europe, positioning South America as an emerging, if still early-stage, destination for regional cross-border patients from neighbouring countries with less developed fertility infrastructure.

Middle East & Africa Assisted Reproductive Technology Market: Israel's Subsidized Model Anchors Regional Utilization

Israel anchors Middle East & Africa ART utilization with one of the world's most generous government-subsidized IVF systems, funding largely unrestricted cycles for citizens up to a specified family size and driving ART utilization rates well above the regional and global average as a direct result. Saudi Arabia and the UAE are expanding fertility clinic capacity as part of broader healthcare investment agendas, with rising domestic demand tied to both infertility prevalence and increasing willingness to seek treatment openly. South Africa's more established private healthcare sector supports steadier ART demand relative to the wider African continent, where clinic density and affordability remain the primary constraints on broader regional growth.

Key Developments

•        In May 2026, Alife Health announced that its product Embryo Predict received clearance from the U.S. Food and Drug Administration, covering its use to help fertility specialists evaluate and select embryos for transfer during in vitro fertilization, one of the most consequential decisions in the IVF process.

•        In May 2025, Greece amended its surrogacy law to require both the intended parent and the surrogate to hold Greek residency, effectively closing the country to new international surrogacy arrangements following a clinic scandal in Crete, while leaving IVF and donor-egg access for international patients unaffected.

•        In March 2025, Alife Health expanded its AI-powered IVF laboratory reporting partnership with US Fertility to more than 100 clinics and 32 laboratories across the United States.

•        In March 2025, Astorg, a leading pan-European private equity firm, announced the launch of Nexpring Health, a global MedTech company dedicated to assisted reproductive technology.

•        In April 2025, Conceivable Life Sciences achieved a successful birth from an AI-automated IVF procedure using ICSI, with 23 critical steps from sperm selection to embryo evaluation performed under remote automation.

•        In September 2024, in the veterinary reproduction space, Indian Immunologicals, in collaboration with the National Dairy Development Board, launched Shashthi, an indigenous IVF media for bovine (cattle) reproduction rather than human ART, aimed at improving dairy herd genetics in India.

•        In January 2024, Ivy Fertility partnered with SMP Pharmacy Solutions, a fertility-focused specialty pharmacy, to streamline the patient experience across Ivy's 13 fertility centers through coordinated services and personalized support.